Cargando…
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
SIMPLE SUMMARY: The treatment of resectable stage III non-small-cell lung cancer with N2 lymph node involvement is usually multimodal and is generally based on neoadjuvant chemotherapy +/− radiotherapy followed by surgery, but the cure rate is still low. Immunotherapy based on anti-PD1/PD-L1 immune...
Autores principales: | Mielgo-Rubio, Xabier, Montemuiño, Sara, Jiménez, Unai, Luna, Javier, Cardeña, Ana, Mezquita, Laura, Martín, Margarita, Couñago, Felipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507745/ https://www.ncbi.nlm.nih.gov/pubmed/34638296 http://dx.doi.org/10.3390/cancers13194811 |
Ejemplares similares
-
Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020) -
Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
por: Aguado, Carlos, et al.
Publicado: (2022) -
Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
por: Aguado, Carlos, et al.
Publicado: (2022) -
Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020) -
Tsunami of immunotherapy reaches mesothelioma
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2022)